Kerri-Ann Millar - Aug 21, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/Kerri-Ann Millar by Colin Sanderock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Aug 21, 2022
Transactions value $
-$8,625
Form type
4
Date filed
8/23/2022, 04:03 PM
Previous filing
Mar 29, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +6.67K +63.67% 17.1K Aug 21, 2022 Direct F1
transaction CUE Common Stock Tax liability -$8.63K -2.83K -16.5% $3.05 14.3K Aug 22, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -6.67K -100% $0.00* 0 Aug 21, 2022 Common Stock 6.67K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020.